# US 2006/0051367 A1 · Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051367 A1
- Document ID: US20060051367A1
- Status: Published application
- Kind: A1
- Application number: 11/267,631
- Filed: 2005-11-03
- Published: 2006-03-09
- Earliest claimed: 1994-07-14
- Assignees: Department Central De Fractionment De La Croix-Rouge Scrl
- Inventors: Ruth Laub; Mario Giambattista
- Web page: https://patentgrep.com/patent/US20060051367A1

## CPC

- G01N 33/6878: {in epitope analysis}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C07K 16/36: against blood coagulation factors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/755: Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
- Y10S 530/806: Antigenic peptides or proteins
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention is related to the antigenic polypeptide sequence of Factor VIII.

## Claims

### Claim 1

An isolated or purified antigenic fragment of a human factor VIII polypeptide, such fragment comprising an epitope of factor VIII, wherein said epitope is the epitope isoleucine 2262 to glutamine 2270 inclusive, defined by the following sequence: Ile Ser Ser Ser Gln Asp Gly His Gln of SEQ ID NO: 30.

### Claim 2 (depends on 2)

A pharmaceutical composition comprising an adequate pharmaceutical carrier and the polypeptide of claim 2.

### Claim 3

An isolated or purified antigenic fragment of a human factor VIII polypeptide, such fragment comprising at least seven amino acids of a human factor VIII C domain positioned between amino acids 2020 and 2332 of SEQ ID NO: 49.

### Claim 4

An isolated or purified antigenic fragment of a human Factor VIII polypeptide, such fragment comprising at least seven amino acids of the human Factor VIII C domain fragment, selected from the group consisting of the following fragments of factor VIII polypeptide of SEQ ID NO: 49, wherein said Factor VIII C domain is positioned between amino acids 2020 and 2332 of SEQ ID NO: 49:
a) a sequence starting from glycine 2242 to tyrosine 2332 inclusive;
b) a sequence starting from glycine 2242 to tyrosine 2305 inclusive;
c) the sequence of (b), wherein one or more amino acids of the terminal peptide Thr-Arg-Tyr are deleted;
d) a sequence starting from isoleucine 2262 to serine 2289 inclusive;
e) a sequence starting from leucine 2273 to tyrosine 2332 inclusive;
f) a sequence starting from leucine 2273 to tyrosine 2305 inclusive;
g) the sequence of (f), wherein one or more amino acids of the terminal peptide Thr-Arg-Tyr are deleted;
h) a sequence starting from proline 2292 to tyrosine 2332 inclusive, and epitopes of the sequences (a) trough (h) selected from the group consisting of:
i) an epitope comprised in the fragment starting from glycine 2242 to leucine 2251 inclusive, defined by the following sequence: Gly Val Thr Thr Gln Gly Val Lys Ser Leu of SEQ ID NO: 29;
j) an epitope comprised in the fragment starting from isoleucine 2262 to glutamine 2270 inclusive, defined by the following sequence: Ile Ser Ser Ser Gln Asp Gly His Gln of SEQ ID NO: 30;
k) an epitope comprised in the fragment starting from leucine 2273 to serine 2289 inclusive, defined by the following sequence: Leu Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp Ser of SEQ ID NO: 31;
l) an epitope comprised in the fragment starting from proline 2292 to tyrosine 2305 inclusive, defined by the following sequence: Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr Arg Tyr of SEQ ID NO: 32;
m) the epitope of (1), wherein one or more amino acids of the terminal tripeptide Thr-Arg-Tyr are deleted;
n) an epitope comprised in the fragment starting from glutamic acid 2322 to tyrosine 2332 inclusive, defined by the following sequence: Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr of SEQ ID NO: 33; and
o) any of the preceding epitopes or sequences (a) through (n), wherein at least one amino acid has been deleted.

### Claim 5 (depends on 4)

A purified or isolated conformational epitope or sequence which contains at least two different epitopes or sequences according to claim 4 and any of the preceding epitopes or sequences wherein at least one amino acid has been deleted.

### Claim 6 (depends on 5)

A complex comprising a carrier protein or a carrier peptide linked to the epitopes according to claim 5.

### Claim 7 (depends on 4)

A complex comprising a carrier protein or a carrier peptide linked to the sequences according to claim 4.

### Claim 8 (depends on 4)

A pharmaceutical composition comprising an adequate pharmaceutical carrier and at least one element selected from the group consisting of domain C of factor VIII of SEQ ID NO: 49, and the antigenic fragment of claim 4.
